Graphic Designer

Work with other creative team members to produce content.
Create guidelines for how logos and other branding materials should be displayed and used.
Help make design choices (e.g., fonts and colors) for all content your company will use.

 MOLOGEN AG concentrated above all on its ongoing clinical studies with the cancer medications MGN1703 and MGN1601. Both studies have progressed as planned. Meanwhile the implementation of the phase II/III colorectal cancer study with MGN1703 could also be started in Russia. The first evaluation of the interim results is scheduled to begin in the second half of 2011. They will be the basis for concluding licensing agreements with a partner from the pharmaceutical industry. The interim evaluation of the phase I/II renal cancer study with the cell-based gene therapy MGN1601 – a further promising medication from the product pipeline in addition to MGN1703 – is due to start soon.

Following major progress with the cancer medication MGN1703 for the treatment of metastatic colorectal cancer in the clinical phase II/III study, MOLOGEN has decided to also clinically test the efficacy of MGN1703 for the treatment of lung cancer. For this purpose, the medication will also be investigated in a clinical study of Phase II/III for the treatment of metastatic non-small cell lung cancer. The application for the new study will be submitted shortly. "With this decision we are expanding the product pipeline of MOLOGEN to include an additional, very promising blockbuster candidate in the clinical development stage. The universal mechanism of action of MGN1703 enables us to use the medication candidate for entirely different cancer indications. This is a decisive competitive advantage for MOLOGEN", explains Dr. Matthias Schroff, Chief Executive Officer of MOLOGEN AG. "We are confidently looking forward to the interim evaluation of our clinical studies and the further developments over the course of the year."